Published in Arthritis Rheum on August 15, 2008
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res (2013) 1.44
Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol (2012) 1.41
Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum (2012) 1.34
Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol (2012) 1.01
The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol (2009) 0.97
The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One (2015) 0.95
Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost (2010) 0.88
Managing cardiovascular risk in patients with chronic inflammatory diseases. Clin Rheumatol (2012) 0.84
Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open (2014) 0.81
Co-Occurrence of Arthritis and Stroke amongst Middle-Aged and Older Adults in Canada. Stroke Res Treat (2014) 0.79
Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol (2016) 0.78
Celecoxib in arthritis: relative risk management profile and implications for patients. Ther Clin Risk Manag (2009) 0.76
Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. PLoS One (2016) 0.75
Ischemic stroke: another feature of accelerated atherosclerosis in rheumatoid arthritis? Arthritis Rheum (2008) 0.75
Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis (2017) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Measurement of patient outcome in arthritis. Arthritis Rheum (1980) 21.31
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Physical activity and stroke risk: a meta-analysis. Stroke (2003) 4.19
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis (2006) 3.48
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol (2007) 3.41
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum (2006) 3.16
Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum (1999) 3.08
A prospective study of body mass index, weight change, and risk of stroke in women. JAMA (1997) 3.04
The many faces of tumor necrosis factor in stroke. Nat Med (2002) 2.33
The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum (1998) 2.30
Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum (2003) 2.29
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) (2000) 2.21
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum (2007) 2.10
Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum (2005) 2.02
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum (2006) 1.94
Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum (2003) 1.83
Adverse effects of corticosteroid therapy for COPD. A critical review. Chest (1997) 1.78
Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med (2005) 1.77
More on "Biased selection of controls for case-control analyses of cohort studies". Biometrics (1986) 1.76
Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis (2004) 1.75
Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. J Rheumatol (2007) 1.74
Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum (2002) 1.55
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab (2003) 1.52
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum (2008) 1.44
Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med (1994) 1.41
Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation (2004) 1.40
Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol (2000) 1.39
Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol (1997) 1.33
C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation (2003) 1.32
Corticosteroids: do they damage the cardiovascular system? Postgrad Med J (1994) 1.32
Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol (1997) 1.27
Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke (1997) 1.21
Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology (Oxford) (2004) 1.16
Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.14
Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum (2004) 1.14
The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am (2005) 1.12
Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly. J Gen Intern Med (2002) 1.06
Targeting the central nervous system inflammatory response in ischemic stroke. Curr Opin Neurol (2001) 1.03
Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med (1987) 1.01
Inflammatory reactions at the blood-endothelial interface in acute stroke. Adv Neurol (1996) 0.89
Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism (1988) 0.83
Does a dose-response relationship reduce sensitivity to hidden bias? Biostatistics (2003) 0.83
TIAs and the pathology of cerebral ischemia. Neurology (2004) 0.77
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med (2006) 10.95
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Rheumatoid arthritis. Lancet (2010) 9.37
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet (2005) 6.61
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther (2009) 3.47
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Ischemic tolerance and endogenous neuroprotection. Trends Neurosci (2003) 3.44
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol (2007) 3.41
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med (2004) 3.36
Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum (2005) 3.31
Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum (2007) 3.16
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum (2006) 3.16
Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum (2003) 3.13
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum (2004) 3.06
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med (2009) 3.03
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
Stop using the American College of Rheumatology criteria in the clinic. J Rheumatol (2003) 2.81
Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 2.70
Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum (2004) 2.57
Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med (2006) 2.36
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol (2004) 2.30
Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol (2006) 2.25
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum (2007) 2.10
HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum (2002) 2.07
Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol (2005) 2.05
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol (2003) 1.97
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab (2003) 1.93
Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum (2003) 1.92
The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol (2007) 1.85
Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum (2007) 1.83
Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol (2005) 1.79
Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J Cereb Blood Flow Metab (2006) 1.75
Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum (2006) 1.73
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.65
Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2007) 1.65
Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol (2005) 1.63
New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res (Hoboken) (2010) 1.57
Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke (2009) 1.56
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol (2005) 1.56
Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis, and fibromyalgia. J Rheumatol (2009) 1.54
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol (2004) 1.53
Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol (2005) 1.52
Jaw pain: its prevalence and meaning in patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia. J Rheumatol (2005) 1.51
Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. J Rheumatol (2004) 1.51
Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum (2009) 1.49
Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum (2007) 1.44
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum (2008) 1.44
Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res (2013) 1.44
Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol (2006) 1.43
Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs. J Clin Rheumatol (2003) 1.42
The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol (2011) 1.40
The impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2017) 1.38
SUMOylation participates in induction of ischemic tolerance. J Neurochem (2009) 1.38
Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol (2010) 1.34
The many myths of erythrocyte sedimentation rate and C-reactive protein. J Rheumatol (2009) 1.34
The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum (2005) 1.31
Effects of intrauterine inflammation on developing rat brain. J Neurosci Res (2002) 1.31
Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum (2009) 1.31
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum (2008) 1.28
Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One (2011) 1.28
A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol (2005) 1.28
Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol (2007) 1.27
Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum (2011) 1.27
Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) (2010) 1.25
Improving the pharmacologic management of pain in older adults: identifying the research gaps and methods to address them. Pain Med (2011) 1.25
Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) (2013) 1.25
The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) (2010) 1.21
Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol (2004) 1.21
Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A (2003) 1.18
Do we need core sets of fibromyalgia domains? The assessment of fibromyalgia (and other rheumatic disorders) in clinical practice. J Rheumatol (2011) 1.17
Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum (2008) 1.17
TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab (2002) 1.12
Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept (2006) 1.12
Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken) (2013) 1.10
Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol (2014) 1.10
The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness. J Rheumatol (2010) 1.10
Determining the fetal inflammatory response in an experimental model of intrauterine inflammation in rats. Pediatr Res (2004) 1.10
The Somatic Symptom Disorder in DSM 5 risks mislabelling people with major medical diseases as mentally ill. J Psychosom Res (2013) 1.09
Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. J Rheumatol (2004) 1.09
Regulation of Akt during torpor in the hibernating ground squirrel, Ictidomys tridecemlineatus. J Comp Physiol B (2010) 1.07